Paediatric porto-sinusoidal vascular disease: Two different clinical phenotypes with subtle histological differences.
children
hepatopulmonary syndrome
hypertransaminasaemia
obliterative portal venopathy
portal hypertension
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
revised:
13
04
2023
received:
02
03
2023
accepted:
23
04
2023
medline:
15
6
2023
pubmed:
9
5
2023
entrez:
9
5
2023
Statut:
ppublish
Résumé
In paediatrics, porto-sinusoidal vascular disease (PSVD) is relatively unknown and probably underdiagnosed. We aimed to describe clinical phenotypes, histology and outcome of children diagnosed with PSVD. Retrospective multicentre study of children diagnosed with PSVD. Diagnosis of PSVD was based on histopathology reports; liver specimens were re-evaluated by two expert liver pathologists. Sixty two children diagnosed with PSVD (M/F = 36/26, median age 6.6 years, range 3.3-10.6), from 7 centres, were included. Thirty-six presented with non-cirrhotic portal hypertension, PH, (PH-PSVD Group = 58%) while 26 had a liver biopsy because of chronic elevation of transaminases without PH (noPH-PSVD Group = 42%). On histology review, the two groups differed for the prevalence of obliterative portal venopathy (more prevalent in PH-PSVD, p = 0.005), and hypervascularised portal tracts (more common in noPH-PSVD, p = 0.039), the other histological changes were equally distributed. At multivariate analysis, platelet count ≤185 000/mm Paediatric patients with PSVD present with two different clinical phenotypes, one characterised by PH and one by chronic elevation of transaminases without PH. PSVD should be included among the conditions causing isolated hypertransaminasaemia. On histology, the differences between the two groups are subtle. Medium-term outcome is favourable in patients without PH; progression of the disease is observed in those with PH.
Sections du résumé
BACKGROUND AND AIMS
In paediatrics, porto-sinusoidal vascular disease (PSVD) is relatively unknown and probably underdiagnosed. We aimed to describe clinical phenotypes, histology and outcome of children diagnosed with PSVD.
METHODS
Retrospective multicentre study of children diagnosed with PSVD. Diagnosis of PSVD was based on histopathology reports; liver specimens were re-evaluated by two expert liver pathologists.
RESULTS
Sixty two children diagnosed with PSVD (M/F = 36/26, median age 6.6 years, range 3.3-10.6), from 7 centres, were included. Thirty-six presented with non-cirrhotic portal hypertension, PH, (PH-PSVD Group = 58%) while 26 had a liver biopsy because of chronic elevation of transaminases without PH (noPH-PSVD Group = 42%). On histology review, the two groups differed for the prevalence of obliterative portal venopathy (more prevalent in PH-PSVD, p = 0.005), and hypervascularised portal tracts (more common in noPH-PSVD, p = 0.039), the other histological changes were equally distributed. At multivariate analysis, platelet count ≤185 000/mm
CONCLUSIONS
Paediatric patients with PSVD present with two different clinical phenotypes, one characterised by PH and one by chronic elevation of transaminases without PH. PSVD should be included among the conditions causing isolated hypertransaminasaemia. On histology, the differences between the two groups are subtle. Medium-term outcome is favourable in patients without PH; progression of the disease is observed in those with PH.
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1523-1536Informations de copyright
© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
De Gottardi A, Rautou PE, Schouten J, et al. Porto-sinusoidal vascular disease: proposal and description of a novel entity. Lancet Gastroenterol Hepatol. 2019;4:399-411.
Goel A, Elias JE, Eapen CE, Ramakrishna B, Elias E. Idiopathic non-cirrhotic intrahepatic portal hypertension (NCIPH)-newer insights into pathogenesis and emerging newer treatment options. J Clin Exp Hepatol. 2014;4:247-256.
Siramolpiwat S, Seijo S, Miquel R, et al. Idiopathic portal hypertension: natural history and long-term outcome. Hepatology. 2014;59:2276-2285.
Chawla Y, Dhiman RK. Intrahepatic portal venopathy andrelated disorders of the liver. Semin Liver Dis. 2008;28:270-281.
Bioulac-Sage P, Le Bail B, Bernard PH, Balabaud C. Hepatoportal sclerosis. Semin Liver Dis. 1995;15:329-339.
Franchi-Abella S, Fabre M, Mselati E, et al. Obliterative portal venopathy: a study of 48 children. J Pediatr. 2014;165:190-193.e2.
De Gottardi A, Sempoux C, Berzigotti A. Porto-sinusoidal vascular disorder. J Hepatol. 2022;77:1124-1135.
Schouten JNL, Garcia-Pagan JC, Valla DC, Janssen HL. Idiopathic noncirrhotic portal hypertension. Hepatology. 2011;54:1071-1081.
Guido M, Sarcognato S, Sonzogni A, et al. Obliterative portal venopathy without portal hypertension: an underestimated condition. Liver Int. 2016;36:454-460.
Cazals-Hatem D, Hillaire S, Rudler M, et al. Obliterative portal venopathy: portal hypertension is not always present at diagnosis. J Hepatol. 2011;54:455-461.
Pugliese N, di Tommaso L, Lleo A, et al. High prevalence of porto-sinusoidal vascular disease in patients with constantly elevated gamma-glutamyl transferase levels. Liver Int. 2022;42:1692-1695.
Gioia S, Riggio O, Nardelli S, d'Amati G, Ridola L. Identifying patients at high risk of developing non-cirrhotic portal hypertension. Hepat Med. 2021;13:105-111.
de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Baveno VII Faculty. Baveno VII-renewing consensus in portal hypertension. J Hepatol. 2022;76:959-974.
Heller C, Schobess R, Kurnik K, et al. Abdominal venous thrombosis in neonates and infants: role of prothrombotic risk factors-a multicenter case-control study. For the childhood thrombophilia study group. Br J Haematol. 2000;111:534-539.
Kmeid M, Liub X, Ballentinec S, Lee H. Idiopathic non-cirrhotic portal hypertension and porto-sinusoidal vascular disease: review of current data. Gastroenterology Res. 2021;14:49-65.
Swartz EN, Sanatani S, Sandor GGS, Schreiber RA. Vascular abnormalities in Adams-Oliver syndrome: cause or effect? Am J Med Genet. 1999;82:49-52.
Guido M, Venancio Alves AF, Balabaud C, Bathal PS, Bioulac-Sage P, et al. Histology of portal vascular changes associated with idiopathic non-cirrhotic portal hypertension: nomenclature and definition. Histopathology. 2019;74:219-226.
Guido M, Pizzi M, Sacerdoti D, Giacomelli L, Rugge M, Bolognesi M. Beyond scoring: a modern histological assessment of chronic hepatitis should include tissue angiogenesis. Gut. 2014;63:1366-1367.
Guido M, Sarcognato S, Sacchi D, Colloredo G. Pathology of idiopathic non-cirrhotic portal hypertension. Virchows Arch. 2018;473:23-31.
Di Giorgio A, D'Antiga L. Portal hypertension. In: D'Antiga L, ed. Pediatric Hepatology and Liver Transplantation. Springer, Cham; 2019. doi:10.1007/978-3-319-96400-3_19
Cantez MS, Gerenli N, Ertekin V, Güllüoğlu M, Durmaz Ö. Hepatoportal sclerosis in childhood: descriptive analysis of 12 patients. J Korean Med Sci. 2013;28:1507-1511.
Ataide EC, Dos Santos IN, Martins DL, et al. Liver failure and the need for transplantation in 6 patients with hepatoportal sclerosis. Transplant Proc. 2013;45:1907-1909.
Fiel MI, Thung SN, Hytiroglou P, Emre S, Schiano TD. Liver failure and need for liver transplantation in patients with advanced hepatoportal sclerosis. Am J Surg Pathol. 2007;31:607-614.
Wanless IR, Peterson P, Das A, Boitnott JK, Moore W, Bernier V. Hepatic vascular disease and portal hypertension in polycythemia vera and agnogenic myeloid metaplasia: a clinicopathological study of 145 patients examined at autopsy. Hepatology. 1990;12:1166-1174.
Hillaire S, Bonte E, Denninger M-H, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension in the west: a re-evaluation in 28 patients. Gut. 2002;51:275-280.
Krasinskas AM, Eghtesad B, Kamath PS, Demetris AJ, Abraham SC. Liver transplantation for severe intrahepatic noncirrhotic portal hypertension. Liver Transpl. 2005;6:627-634.
Wanless IR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology. 1990;11:787-797.
Hollande C, Mallet V, Darbeda S, et al. Impact of obliterative portal venopathy associated with human immunodeficiency virus. Medicine. 2016;95:e3081.
Austin A, Campbell E, Lane P, Elias E. Nodular regenerative hyperplasia of the liver and coeliac disease: potential role of IgA anticardiolipin antibody. Gut. 2004;53:1032-1034.
Malamut G, Ziol M, Suarez F, et al. Nodular regenerative hyperplasia: the main liver disease in patients with primary hypogammaglobulinemia and hepatic abnormalities. J Hepatol. 2008;48:74-82.
Leung VK, Loke TK, Luk IS, et al. Nodular regenerative hyperplasia of the liver associated with systemic lupus erythematosus: three cases. Hong Kong Med J. 2009;15:139-142.
Kotani K, Kawabe J, Morikawa H, Akahoshi T, Hashizume M, Shiomi S. Comprehensive screening of gene function and networks by DNA microarray analysis in Japanese patients with idiopathic portal hypertension. Mediators Inflamm. 2015;2015:349215.
Saito K, Nakanuma Y, Takegoshi K, et al. Non-specific immunological abnormalities and association of autoimmune diseases in idiopathic portal hypertension. A study by questionnaire. Hepato-Gastoenterol. 1993;40:163-166.
Besmond C, Valla D, Hubert L, et al. Mutations in the novel gene FOPV are associated with familial autosomal dominant and non-familial obliterative portal venopathy. Liver Int. 2018;38:358-364.
Bart Koot GP, Alders M, Verheij J, Beuers U, Cobben JM. A de novo mutation in KCNN3 associated with autosomal dominant idiopathic non-cirrhotic portal hypertension. J Hepatol. 2016;64:974-977.
Girard M, Amiel J, Fabre M, Pariente D, Lyonnet S, Jacquemin E. Adams-Oliver syndrome and hepatoportal sclerosis: occasional association or common mechanism? Am J Med Genet Part. 2005;135A:186-189.
Pouessel G, Dieux-Coeslier A, Wacrenier A, Fabre M, Gottrand F. Association of Adams-Oliver syndrome and hepatoportal sclerosis: an additional case. Am J Med Genet. 2006;140:1028-1029.
Aminkeng F. DLL4 loss-of-function heterozygous mutations cause Adams-Oliver syndrome. Clin Genet. 2015;88:532.
Nayak NC. Idiopathic portal hypertension (noncirrhotic portal fibrosis), thrombosis in portal venous system and protein C deficiency. Hepatology. 1989;10:902.
Girard C, Laborde N, Marbach C, Mas E, Bureau C, Broué P. Porto-sinusoidal vascular disease: a pediatric study of 30 patients. J Pediatr Gastroenterol Nutr. 2022;74:e132-e137.
Matsutani S, Maruyama H, Akiike T, et al. Study of portal vein thrombosis in patients with idiopathic portal hypertension in Japan. Liver Int. 2005;25:978-983.
Di Giorgio A, De Angelis P, Cheli M, et al. Etiology, presenting features and outcome of children with non-cirrhotic portal vein thrombosis: a multicentre national study. Dig Liver Dis. 2019;51:1179-1184.